Introduction
The term "anetoderma" originates from the Greek words anetos (relaxed) and derma (skin). First described by Jadassohn in 1892, anetoderma is a benign disorder of elastolysis characterized by well-circumscribed, focal areas of flaccid skin. Clinically, these lesions appear as round to oval atrophic depressions, wrinkled macules, patches, or herniated sac-like protrusions surrounded by normal skin. The lesions may be skin-colored, white, gray, brown, or blue and can measure from millimeters to centimeters. Anetoderma most commonly affects the trunk and proximal extremities.[1] Once present, the disease remains active for at least 15 years.[2] Spontaneous regression has never been reported.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Anetoderma is classified into 5 subtypes: primary (idiopathic), secondary to a preceding dermatosis, drug-induced, familial, and prematurity-associated. The primary type occurs in areas of previously normal skin and is historically subdivided into the Jadassohn-Pellizzari and Schweninger-Buzzi types. The Jadassohn-Pellizzari type develops after preceding inflammatory or urticarial lesions, while the Schweninger-Buzzi type arises in normal-appearing skin without prior changes. These subtypes are histologically identical and follow a similar disease course, rendering the terms obsolete.
The secondary type develops in areas of pathologic skin.[3] The most commonly associated dermatoses are acne vulgaris and varicella, but cases have also been reported with syphilis, sarcoidosis, tuberculosis, leprosy, Lyme disease, mastocytosis, prurigo nodularis, urticaria pigmentosa, granuloma annulare, insect bites, xanthomas, pilomatricomas, cutaneous B- or T-cell lymphomas, posthepatitis B vaccination, hamartomatous congenital melanocytic nevi, leech application, molluscum contagiosum, myxofibrosarcoma, and nodular amyloidosis.[4][5][6]
Reports have linked both primary and secondary anetoderma to HIV-1 infection and autoimmune diseases such as systemic lupus erythematosus (SLE), Graves disease, Addison disease, antiphospholipid syndrome (APS), Sjögren syndrome, and hemolytic anemia.[7][8] In recent years, anetoderma has also been associated with the COVID-19 vaccine and disseminated MPOX virus.[9][10]
Penicillamine is the only medication linked to drug-induced anetoderma, likely due to its inhibition of aldol cross-linking, a process essential for elastic fiber formation. The familial form of anetoderma is rare and follows an autosomal inheritance pattern, typically developing in the 1st decade of life. This form may present as isolated skin findings or occur with bony, neurological, and ocular anomalies.[11] Anetoderma of prematurity affects neonates born at 24 to 29 weeks of gestation who required monitoring while in the neonatal intensive care unit.
Epidemiology
Anetoderma is a rare disorder with an uncertain prevalence. This skin disorder has been reported across all age groups but most commonly affects adults aged 20 to 40 years. The condition is more frequent in female than male individuals and shows no racial predilection.
Pathophysiology
The exact pathophysiology of anetoderma remains uncertain. All forms of anetoderma involve a reduction in elastic tissue, potentially due to decreased elastin production, increased elastin degradation by elastolytic enzymes, reduced elastolytic enzyme inhibitors, or enhanced elastin phagocytosis. In penicillamine-induced anetoderma, inhibition of aldol cross-linking disrupts normal elastic fiber development. Anetoderma of prematurity is hypothesized to result from tissue hypoxia caused by adhesive medical devices, which may upregulate matrix metalloproteinase expression, leading to elastin degradation.[12]
Histopathology
Microscopically, anetoderma is characterized by focal loss or marked reduction of elastic fibers in the mid-to-reticular dermis, best visualized with special stains such as Verhoeff-Van Gieson or Orcein. The overlying epidermis remains unaffected, and the dermis may exhibit mild perivascular lymphocytic infiltration. Inflammatory variants show early elastophagocytosis by histiocytes or mast cells, whereas noninflammatory forms display passive elastic fiber loss. Collagen structure is typically preserved, though some cases demonstrate dermal atrophy. The absence of fibrosis distinguishes anetoderma from other elastolytic disorders, highlighting its unique pathophysiologic mechanism.[13]
History and Physical
Early lesions of anetoderma are typically asymptomatic or present as pruritic erythematous macules, plaques, or nodules that enlarge until reaching their final size. These manifestations may also be observed in areas of pathologic skin, as seen in the secondary type. Lesions can be solitary or multiple, appearing as discrete, flaccid areas of loose, wrinkled skin that may be depressed or protruding. On palpation, a normal skin ring is perceptible at the perimeter, while central pressure causes inward herniation. Once fully developed, lesions remain unchanged over time.
Evaluation
The diagnosis of anetoderma is primarily clinical. However, if uncertain, a skin biopsy, preferably a punch biopsy including the middermis, may be performed. Once diagnosed, the subtype should be determined based on the patient’s history.
On electron microscopy, lesional skin may show elastophagocytosis and small, fragmented elastic fibrils.[14][15] Desmosine, a major amino acid in elastin, has been used to quantify elastin concentration in affected skin, which is significantly reduced in anetoderma.[16]
Patients with primary anetoderma may require additional testing to identify associated underlying diseases. Workup should be guided by clinical suspicion based on history and physical examination. Given the association between primary anetoderma and antiphospholipid antibodies, testing is recommended in all cases, even in the absence of thrombotic disease or recurrent pregnancy loss.
Treatment / Management
Various medical treatments for anetoderma have been attempted, but none have proven effective for established lesions. Colchicine has demonstrated efficacy in preventing new primary anetoderma lesions.[17] In secondary anetoderma, controlling the underlying dermatosis may help prevent the formation of additional lesions.(B3)
Other treatments, including cryotherapy, intralesional steroids, hydroxychloroquine, vitamin E, oral penicillin G, epsilon-aminocaproic acid, aspirin, niacin, dapsone, and phenytoin, have been used but lack studied efficacy. Established lesions may be surgically excised for definitive treatment, though this approach results in permanent scarring. Laser therapy may improve lesion appearance, according to limited case reports.[18][19](B3)
Differential Diagnosis
Diseases commonly mistaken for anetoderma primarily involve disorders of elastic tissue that lead to cutaneous atrophy. Middermal elastolysis is characterized by the loss of middermal elastic fibers, resulting in widespread, well-defined, thin, and wrinkled plaques, typically on the trunk and upper arms. In acquired cutis laxa, elastic fiber loss causes generalized loose, sagging skin. Granulomatous slack skin disease, a rare variant of cutaneous T-cell lymphoma, presents with phagocytized elastic fibers and erythematous, pendulous folds of loose skin. Atrophoderma of Pasini and Pierini manifests as brown, gray, or violaceous macules or patches with a distinct sloping "cliff-drop" border on palpation, most commonly on the trunk.
Prognosis
The prognosis of anetoderma depends on its underlying cause. Primary anetoderma is typically benign, with lesions remaining stable or slowly progressing without systemic complications. In contrast, secondary anetoderma may indicate an associated autoimmune, infectious, or hematologic disorder, potentially contributing to morbidity and mortality. While skin lesions are irreversible, early identification and management of an underlying condition may prevent further progression. The psychosocial impact of disfigurement can be significant, warranting supportive care. Long-term follow-up is recommended, especially in cases linked to systemic disease, to monitor for progression or emerging comorbidities.
Complications
Complications of anetoderma primarily arise from its association with underlying systemic diseases rather than the skin lesions themselves. Secondary anetoderma may signal autoimmune conditions such as SLE or APS, where vascular thrombosis and systemic inflammation increase the risk of spontaneous abortion. Inflammatory or infectious causes, including syphilis and leprosy, can lead to progressive tissue damage if untreated. While lesions are typically asymptomatic, extensive involvement may result in cosmetic disfigurement and psychosocial distress. Rare cases of association with hematologic malignancies have been reported, necessitating thorough systemic evaluation in the presence of atypical features. Given the condition's chronic and often progressive nature, long-term monitoring is essential.[20]
Deterrence and Patient Education
Anetoderma is a benign skin condition, and once diagnosed, determining its subtype is essential. This classification helps predict the disease course and guide management, particularly in secondary anetoderma, where addressing underlying factors may prevent new lesions. Patient education should emphasize the nature of the disease, its progression, and the irreversible nature of established lesions.
Enhancing Healthcare Team Outcomes
Anetoderma is a rare disease best managed by an interprofessional team, including primary care clinicians, dermatologists, and pathologists. Primary care clinicians should recognize this benign condition and determine its subtype to monitor for associated disorders and guide appropriate management. Nurses play a key role in patient education, reinforcing understanding of the disease and its course. Effective communication within the team is essential for optimizing patient outcomes.
References
Kineston DP, Xia Y, Turiansky GW. Anetoderma: a case report and review of the literature. Cutis. 2008 Jun:81(6):501-6 [PubMed PMID: 18666393]
Level 3 (low-level) evidenceVenencie PY, Winkelmann RK, Moore BA. Anetoderma. Clinical findings, associations, and long-term follow-up evaluations. Archives of dermatology. 1984 Aug:120(8):1032-9 [PubMed PMID: 6465909]
Level 3 (low-level) evidencede Faria Melo M, de Faria Melo I, Escobar GF. Secondary Anetoderma. JAMA dermatology. 2021 Apr 14:():. doi: 10.1001/jamadermatol.2021.0440. Epub 2021 Apr 14 [PubMed PMID: 33851962]
Barbosa J, João AL, João A, Fernandes C. Secondary Syphilis-Induced Anetoderma. Actas dermo-sifiliograficas. 2024 Sep:115(8):838-840. doi: 10.1016/j.ad.2022.11.021. Epub 2023 Oct 4 [PubMed PMID: 37797881]
Sparsa A, Piette JC, Wechsler B, Amoura Z, Francès C. Anetoderma and its prothrombotic abnormalities. Journal of the American Academy of Dermatology. 2003 Dec:49(6):1008-12 [PubMed PMID: 14639377]
Daoud MS, Dicken CH. Anetoderma after hepatitis B immunization in two siblings. Journal of the American Academy of Dermatology. 1997 May:36(5 Pt 1):779-80 [PubMed PMID: 9146542]
Level 3 (low-level) evidenceMartín Carmona J, Gómez Moyano E, Ayala Blanca M, Martínez Pilar L. Anetoderma associated with antiphospholipid syndrome. Medicina clinica. 2020 Apr 10:154(7):288. doi: 10.1016/j.medcli.2019.04.036. Epub 2019 Jul 28 [PubMed PMID: 31362832]
Esquivel-Valerio JA, Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Disseminated anetoderma associated with antiphospholipid antibodies. Clinical rheumatology. 2020 Dec:39(12):3887-3888. doi: 10.1007/s10067-020-05321-y. Epub 2020 Aug 10 [PubMed PMID: 32776312]
Massi A, Rapparini L, Misciali C, Baraldi C, Pileri A. Anetoderma after mRNA COVID-19 vaccine. Italian journal of dermatology and venereology. 2023 Jun:158(3):269-270. doi: 10.23736/S2784-8671.23.07305-X. Epub [PubMed PMID: 37278506]
Grau-Echevarría A, Labrandero-Hoyos C, Peñuelas-Leal R, Finello M, Blaya-Imbernón D, García-García JÁ, Berenguer-Romero MD, de Miquel VA, Pérez-Ferriols A, Martínez-Calabuig P, Hernández-Bel P. Anetoderma after disseminated Mpox. Journal of cutaneous pathology. 2024 Jun:51(6):415-418. doi: 10.1111/cup.14606. Epub 2024 Mar 12 [PubMed PMID: 38468572]
Patrizi A, Neri I, Virdi A, Misciali C, D'Acunto C. Familial anetoderma: a report of two families. European journal of dermatology : EJD. 2011 Sep-Oct:21(5):680-5. doi: 10.1684/ejd.2011.1450. Epub [PubMed PMID: 21719400]
Level 3 (low-level) evidenceGhomrasseni S, Dridi M, Gogly B, Bonnefoix M, Vabres P, Venencie PY, Pellat B, Godeau G. Anetoderma: an altered balance between metalloproteinases and tissue inhibitors of metalloproteinases. The American Journal of dermatopathology. 2002 Apr:24(2):118-29 [PubMed PMID: 11979071]
Venencie PY, Winkelmann RK. Monoclonal antibody studies in the skin lesions of patients with anetoderma. Archives of dermatology. 1985 Jun:121(6):747-9 [PubMed PMID: 3873911]
Venencie PY, Winkelmann RK. Histopathologic findings in anetoderma. Archives of dermatology. 1984 Aug:120(8):1040-4 [PubMed PMID: 6465910]
Zaki I, Scerri L, Nelson H. Primary anetoderma: phagocytosis of elastic fibres by macrophages. Clinical and experimental dermatology. 1994 Sep:19(5):388-90 [PubMed PMID: 7955494]
Level 3 (low-level) evidenceOikarinen AI, Palatsi R, Adomian GE, Oikarinen H, Clark JG, Uitto J. Anetoderma: biochemical and ultrastructural demonstration of an elastin defect in the skin of three patients. Journal of the American Academy of Dermatology. 1984 Jul:11(1):64-72 [PubMed PMID: 6736354]
Braun RP, Borradori L, Chavaz P, Masouyé I, French L, Saurat JH. Treatment of primary anetoderma with colchicine. Journal of the American Academy of Dermatology. 1998 Jun:38(6 Pt 1):1002-3 [PubMed PMID: 9632017]
Level 3 (low-level) evidenceCho S, Jung JY, Lee JH. Treatment of anetoderma occurring after resolution of Stevens-Johnson syndrome using an ablative 10,600-nm carbon dioxide fractional laser. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2012 Apr:38(4):677-9. doi: 10.1111/j.1524-4725.2011.02272.x. Epub 2012 Jan 17 [PubMed PMID: 22251221]
Level 3 (low-level) evidenceWang K, Ross NA, Saedi N. Anetoderma treated with combined 595-nm pulsed-dye laser and 1550-nm non-ablative fractionated laser. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology. 2016:18(1):38-40. doi: 10.3109/14764172.2015.1039039. Epub 2015 Jul 3 [PubMed PMID: 25968163]
Hodak E, David M. Primary anetoderma and antiphospholipid antibodies--review of the literature. Clinical reviews in allergy & immunology. 2007 Apr:32(2):162-6 [PubMed PMID: 17916987]